Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05377112 · ClinicalTrials.gov registry record · Early Phase 1
Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome
A Early Phase 1 study, sponsored by Synlogic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT05377112 is a Early Phase 1 study that has completed, run by Synlogic. The registered enrollment target is 11 participants.
The verdict
NCT05377112, a Early Phase 1 study, has completed, sponsored by Synlogic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Study SYNB8802-CP-002 is designed to assess safety, tolerability, and oxalate lowering, in subjects with a history of gastric bypass surgery or short-bowel syndrome. In addition, this study will explore other PD effects relative to baseline as well as predictors of efficacy and tolerability.
Interventions
- OTHER Placebo
- DRUG SYNB8802v1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2022-12-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05377112
The ClinicalTrials.gov registry entry for NCT05377112 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synlogic, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05377112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05377112 about?
NCT05377112 is a clinical study titled "Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome". Study SYNB8802-CP-002 is designed to assess safety, tolerability, and oxalate lowering, in subjects with a history of gastric bypass surgery or short-bowel syndrome. In addition, this study will explore other PD effects relative to baseline as well as predictors of efficacy and tolerability.
What is the current status of trial NCT05377112?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2022-03-29. Estimated completion is 2022-12-07.
What interventions are being tested in trial NCT05377112?
The interventions under investigation include: Placebo (OTHER), SYNB8802v1 (DRUG).
Who is sponsoring clinical trial NCT05377112?
This trial is sponsored by Synlogic, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.